# US 11,077,181 B2 · Vaccine comprising a PCV2 ORF2 protein of genotype 2b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,181 B2
- Document ID: US11077181B2
- Status: Granted
- Kind: B2
- Application number: 16/634,756
- Filed: 2018-08-02
- Published: 2020-07-02
- Granted: 2021-08-03
- Earliest claimed: 2017-08-03
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Melanie Sno; Erik Cox; Ruud Philip Antoon Maria Segers
- Web page: https://patentgrep.com/patent/US11077181B2

## CPC

- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 μg per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

## Claims

### Claim 1

A method of protecting a pig against an infection with porcine circo virus type 2, comprising administering to the pig a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, wherein the vaccine comprises less than 20 μg per dose of the ORF2 encoded protein, wherein the protein is of a porcine circo virus of genotype 2b; and wherein the vaccine provides protection against PCV2 of genotype 2d at a level corresponding to the protection conferred when the pig is vaccinated with an ORF2 encoded protein of PCV2d.

### Claim 2 (depends on 1)

The method of claim 1, wherein the vaccine comprises less than 5 μg per dose of the ORF2 encoded protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vaccine is for protecting pigs that have antibodies against PCV2.

### Claim 4 (depends on 3)

The method of claim 3, wherein the antibodies against PCV2 are of maternal origin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pig is 4 weeks old or less.

### Claim 6 (depends on 1)

The method of claim 1, wherein the vaccine provides protection after one single administration of the vaccine.

### Claim 7 (depends on 4)

The method of claim 4, wherein the vaccine comprises less than 5 μg per dose.

### Claim 8 (depends on 4)

The method of claim 4, wherein one single dose of the vaccine is administered to arrive at the protection.